AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

Shares of Akero Therapeutics (AKRO) skyrocketed 105.7% in a week after the company announced initial positive top line 96-week data from a mid-stage study of its lead product candidate, efruxifermin (EFX), for liver disease. The phase IIb SYMMETRY study evaluated two doses of EFX (28mg and 50mg) compared with a placebo in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH).Per the data readout, in patients with both ba ...